- Supply agreement supports Viridian’s development of potential first- and best-in-class subcutaneous therapies for treatment of thyroid eye disease (TED) - - Ypsomed brings strong track record of ...
Toronto, Ontario--(Newsfile Corp. - August 21, 2025) - NuGen Medical Devices Inc. (NGMD:CA) ("NuGen" or the "Company"), a leader in needle-free subcutaneous drug-delivery technology, is pleased to ...
CINCINNATI (WKRC) - A company in Evendale is changing medicine through a breakthrough device that gives patients a way to take certain medications at home. Its purpose is to redefine drug delivery.
ONAPGO, a subcutaneous infusion device, treats motor fluctuations in advanced Parkinson's disease and launches in the U.S. in 2025. Supernus Pharmaceuticals has announced the FDA approval of ONAPGO, ...
Enable Injections, maker of manual and connected adhesive wearables for subcutaneously therapeutic delivery, has raised $50 million in a Series B round led by Sanofi, the company announced today. ORI ...
Subcutaneous Sarclisa, administered via OBDS, showed non-inferior efficacy to IV Sarclisa in relapsed/refractory multiple myeloma patients. The IRAKLIA study enrolled 532 patients globally, ...
Sanofi has turned to Blackstone Life Sciences for help developing a subcutaneous formulation of multiple myeloma drug Sarclisa. Blackstone is putting up $300 million to fund development of the ...
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results